Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 31.01% | -38.67% | -2.80% | 12.06% | 27.96% |
| Total Depreciation and Amortization | 1.19% | -6.67% | 8.53% | 0.87% | -1.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -59.98% | 200.63% | -75.38% | 45.41% | 92.26% |
| Change in Net Operating Assets | 53.81% | -314.47% | 552.76% | 108.13% | -686.27% |
| Cash from Operations | 62.37% | -65.55% | -1.40% | 82.83% | -13.07% |
| Capital Expenditure | 43.19% | -72.03% | -6.95% | -30.31% | 54.48% |
| Sale of Property, Plant, and Equipment | 400.00% | 0.00% | 0.00% | -90.00% | -78.72% |
| Cash Acquisitions | -938.91% | -1,146.24% | 94.41% | -- | -- |
| Divestitures | 77.78% | 85.94% | -481.82% | -175.00% | -102.44% |
| Other Investing Activities | 297.56% | 6.29% | -47.06% | -141.18% | 125.58% |
| Cash from Investing | -457.79% | -144.65% | 61.66% | -779.70% | 110.88% |
| Total Debt Issued | 127.57% | 3,697.04% | -84.12% | 52.88% | 2,416.67% |
| Total Debt Repaid | 95.01% | -185.29% | 3.44% | 38.00% | -1,215.85% |
| Issuance of Common Stock | -- | 100.00% | -90.00% | 1,900.00% | -- |
| Repurchase of Common Stock | -26.69% | 35.71% | 15.18% | 0.07% | 1.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 53.40% | -- |
| Other Financing Activities | 162.90% | -663.64% | 110.23% | -1,034.78% | 117.97% |
| Cash from Financing | 112.66% | 160.34% | 46.50% | 39.01% | -185.31% |
| Foreign Exchange rate Adjustments | -313.89% | 263.64% | -105.76% | 112.22% | 157.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -342.58% | -35.21% | 807.32% | 90.67% | -104.33% |